問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Linkou Chang Gung Medical Foundation

List

2449Cases

2021-02-01 - 2027-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2018-11-01 - 2023-12-31

Phase III

Completed
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (RHINE)

  • Condition/Disease

    Diabetic Macular Edema

  • Test Drug

    FARICIMAB (RO6867461)

Participate Sites
3Sites

Terminated3Sites

2019-03-01 - 2023-12-31

Phase III

Completed
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (LUCERNE)

  • Condition/Disease

    nAMD

  • Test Drug

    Faricimab (RO6867461) Eylea

Participate Sites
4Sites

Terminated4Sites

2020-09-01 - 2024-10-09

Phase III

Completed
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion

  • Condition/Disease

    Macular Edema Secondary to Branch Retinal Vein Occlusion

  • Test Drug

    FARICIMAB (RO6867461)

Participate Sites
4Sites

Not yet recruiting4Sites

2020-09-01 - 2024-09-18

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-12-01 - 2024-06-30

Phase III

Completed
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA

  • Condition/Disease

    Diabetic Macular Edema

  • Test Drug

    FARICIMAB (RO6867461)

Participate Sites
3Sites

Recruiting3Sites

2021-05-01 - 2024-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2017-06-15 - 2025-12-31

Phase III

Completed
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

  • Condition/Disease

    Metastatic Castrate-Resistant Prostate Cancer

  • Test Drug

    IPATASERTIB

Participate Sites
6Sites

Terminated4Sites

林永昌
Linkou Chang Gung Medical Foundation

黃書彬
Kaohsiung Municipal Gangshan Hospital

未分科

2017-02-01 - 2021-12-27

Phase III

Completed
A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN

  • Condition/Disease

    Prostatic Neoplasms, Castration-Resistant

  • Test Drug

    Atezolizumab

Participate Sites
4Sites

Terminated4Sites

林永昌
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2016-06-01 - 2024-06-28

Phase III

Completed
A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH GEMCITABINE/CARBOPLATIN VERSUS GEMCITABINE/CARBOPLATIN ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLATIN-BASED THERAPY

  • Condition/Disease

    LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

  • Test Drug

    TECENTRIQ (Atezolizumab)

Participate Sites
7Sites

Terminated6Sites

莊正鏗
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

1 2 3 4 5 245
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB